Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 31 to 45 of 137 results for multiple sclerosis

  1. Can vitamin D slow down the progression of disability in Multiple Sclerosis (MS)?

    Question Can vitamin D slow down the progression of disability in Multiple Sclerosis (MS)? Any explanatory notes(if...

    Research recommendation
    Published
    9 June 2015

  2. What is the clinical and cost effectiveness of cognitive rehabilitation for people with Multiple sclerosis (MS)?

    people with Multiple sclerosis (MS)? Any explanatory notes(if applicable) Cognitive impairment affects 43–70% of people...

    Research recommendation
    Published
    9 June 2015

  3. What non-pharmacological interventions are effective in reducing spasticity in people with Multiple Sclerosis (MS)?

    with Multiple Sclerosis (MS)? Any explanatory notes(if applicable) Spasticity is a common symptom affecting up to 80% of...

    Research recommendation
    Published
    9 June 2015

  4. Autologous unmanipulated peripheral blood stem cell therapy for multiple sclerosis

    Register an interest in this interventional procedure NICE has been notified about the above procedure and considered it part of the In...

    Interventional procedures guidance
    Topic selection

  5. What is the optimal frequency, intensity and form of rehabilitation for mobility problems in people with Multiple Sclerosis (MS)?

    people with Multiple Sclerosis (MS)? Any explanatory notes(if applicable) Reduced mobility is one of the most common...

    Research recommendation
    Published
    9 June 2015

  6. Is intravenous methylprednisolone more clinically and cost effective than oral methylprednisolone in people with relapsing–remitting Multiple Sclerosis (MS) and people with secondary progressive MS with continued relapses?

    methylprednisolone in people with relapsing–remitting Multiple Sclerosis (MS) and people with secondary progressive...

    Research recommendation
    Published
    9 June 2015

  7. Subcutaneous ocrelizumab for treating primary progressive or relapsing multiple sclerosis TS ID 11895

      Status ...

    Technology appraisal guidance
    Topic selection

  8. NICE recommends the development of patient registries for multiple sclerosis to capture long-term treatment-related outcomes.

    Question NICE recommends the development of patient registries for multiple sclerosis to capture long-term treatment-related outcomes....

    Research recommendation
    Published
    9 June 2015

  9. NICE recommends further research to better inform future cost-effectiveness models of relapsing-remitting multiple sclerosis. In particular, this research should include a more comprehensive synthesis of available evidence on the underlying disease progression of multiple sclerosis in the UK context, the impact of disability and relapses on preference-based measures of quality of life, and associated resource use and costs.

    better inform future cost-effectiveness models of relapsing-remitting multiple sclerosis. In particular, this research should include a...

    Research recommendation
    Published
    9 June 2015

  10. Types of technology appraisal recommendation

    The technology appraisal committee can make 5 types of recommendation: Recommended, Optimised, Recommended for use in the Cancer Drugs Fund, Only in research, and Not recommended.

  11. ODFS Pace and Pace XL functional electrical stimulation devices for treating drop foot (MIB56)

    NICE has developed a medtech innovation briefing (MIB) on the ODFS Pace and Pace XL functional electrical stimulation devices for treating drop foot

    Medtech innovation briefing
    Published
    11 March 2016

  12. Dimethyl fumarate for treating relapsing-remitting multiple sclerosis in people aged 13 to 17 TS ID 11778

      Status ...

    Technology appraisal guidance
    Topic selection

  13. Faecal incontinence in adults: management (CG49)

    This guideline covers assessing and managing faecal incontinence (any involuntary loss of faeces that is a social or hygienic problem) in people aged 18 and over. It aims to ensure that staff are aware that faecal incontinence is a sign or a symptom, not a diagnosis. It aims to improve the physical and mental health and quality of life of people with faecal incontinence.

    Clinical guideline
    Published
    27 June 2007
    View recommendations

    Sections for CG49

  14. Sipavibart for preventing COVID-19 [ID6282]

    In development [GID-TA11352] Expected publication date: TBC

    Technology appraisal guidance
    In development

  15. NICE recommends that a new model for multiple sclerosis is developed, ideally based on UK patient cohorts, which uses the best available evidence (including experience to date from the risk-sharing scheme) and includes all currently available treatments.

    TA254/2 Question NICE recommends that a new model for multiple sclerosis is developed, ideally based on UK patient cohorts, which uses...

    Research recommendation
    Published
    9 June 2015